Skip to main content


Log in

Relationship between age, renal function and bone mineral density in the US population

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript


Bisphosphonate drugs for treating osteoporosis are excreted by the kidney. However, many of the major trials on efficacy and safety of the bisphophonates for treating osteoporosis excluded patients with significant renal compromise. Since both osteoporosis and renal insufficiency become more prevalent with age, it seems prudent for physicians to be aware of the prevalence of renal dysfunction in patients with osteoporosis who are candidates for treatment with bisphosphonates. Data on 13,831 men and women aged 20+ from the Third National Health and Nutrition Examination Survey, 1988–1994 (NHANES III) were used to study the occurrence of compromise in renal clearance function in men and women with osteopenia and osteoporosis. To estimate creatinine clearance (CCr), a measure of renal function, serum creatinine (sCr), weight and age were inserted into the Cockcoft-Gault (C-G) formula. The World Health Organization gender specific bone mineral density (BMD) cut-offs were used to define the populations with osteopenia and osteoporosis. For women ages 20–80+ with osteoporosis, the percent prevalence (95% CI) for mild to moderate compromise of CCr ≤60 ml/min is estimated to be 85% (79%, 91%) and for severe renal compromise of CCr <35 ml/min to be 24% (19%, 29%). In women with osteoporosis and severe compromise, the age specific prevalence is negligible through ages 50–59 and then rises steeply to 54% (46%, 62%) for ages 80+. Similarly, in women with osteopenia and severe renal compromise, the age specific prevalence is also negligible through ages 50–59 and then rises to 37% (28%, 45%) for ages 80+. Lower prevalence estimates hold for men with about 11% of men with osteoporosis having severe renal compromise as compared to 24% for women. These data suggest that there is a substantial prevalence of candidates for treatment of osteoporosis and osteopenia who have significant renal compromise but for whom there is a dearth of clinical trial data on the impact of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1.
Fig. 2.

Similar content being viewed by others


  1. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K et al. (1993) Bone density at various sites for prediction of hip fractures. Lancet 341:72–75

    CAS  PubMed  Google Scholar 

  2. Melton LJ III, Kan SH, Wahner HW, Riggs BL (1988) Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol 41:985–994

    PubMed  Google Scholar 

  3. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL (1993) Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:1227–1233

    PubMed  Google Scholar 

  4. Ross PD, Wasnich RD, Davis JW (1990) Fracture prediction models for osteoporosis prevention. Bone 11:327–331

    CAS  PubMed  Google Scholar 

  5. Looker AN, Johnston CC Jr, Wahner HW, Dunn WL, Calvo MS, Harris TB et al. (1995) Prevalence of low femoral bone density in older US women from NHANES III. J Bone Miner Res 10:796–802

    CAS  PubMed  Google Scholar 

  6. Looker AN, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL et al. (1997) Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12:1761–1768

    CAS  PubMed  Google Scholar 

  7. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J et al. (1998) Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kid Dis 32:992–999

    CAS  PubMed  Google Scholar 

  8. National Center for Health Statistics (1994) Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988–1994, Vital Health Stat 1(32). DHHS Publication No. (PHS) 94-1308. NCHS, Hyattsville, Md.

  9. Mohadjer, L. Montaquila J. Waksberg J, Bell B. James P, Flores-Cervantes I, Montes M (1996) National Health and Nutrition Examination Survey III. Weighting and estimation methodology. Westat Inc., Rockville, Md.

  10. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    CAS  PubMed  Google Scholar 

  11. Siris E (2000) Alendronate in the treatment of osteoporosis: a review of the clinical trials. J Women's Health Gend Based Med 9:599–606

    Google Scholar 

  12. Watts NB (1998) Treatment of osteoporosis with bisphosphonates. Endocrinol Metab Clin N Am 27:419–439

    CAS  Google Scholar 

  13. Black DM, Cummings SR, Karpf DB Cauley JA, Thompson DE, Nevitt MC et al. (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541

    CAS  PubMed  Google Scholar 

  14. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras, AG (1993) Clinical pharmacology of alendronate sodium. Osteoporos Int Suppl. 2:S13–16

    Google Scholar 

  15. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH et al. (1995) Effects of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443

    CAS  PubMed  Google Scholar 

  16. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D et al. (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 12:1–12

    CAS  Google Scholar 

  17. Pols HA, Flesenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ et al. (1999) Multinational, placebo-controlled trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468

    Article  CAS  PubMed  Google Scholar 

  18. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340

    Article  CAS  PubMed  Google Scholar 

  19. Mitchell DY, St Peter JV, Pallone KA, Kelly SC, Russell DA, Nesbitt JD, Thompson GA, Powell JH (2000) Effects of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 49:215–222

    Article  CAS  PubMed  Google Scholar 

  20. Yendt ER, Cohanim M, Jarzylo S, Jones G, Rosenberg G (1991) Bone mass is related to creatinine clearance in normal elderly women. J Bone Miner Res 6:1043–1050

    CAS  PubMed  Google Scholar 

  21. Yendt ER, Cohanim M, Jarzylo S, Jones G, Rosenberg G (1993) Reduced creatinine clearance in primary osteoporosis in women. J Bone Miner Res 8:1045–1052

    CAS  PubMed  Google Scholar 

Download references


The authors of this manuscript gratefully acknowledge the financial support of this work from Procter and Gamble Pharmaceuticals, Inc.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Sidney Klawansky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klawansky, S., Komaroff, E., Cavanaugh, P.F. et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14, 570–576 (2003).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: